Premium
Neovascular glaucoma anti‐VEGF treatment
Author(s) -
ZOGRAFOS L
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.3263.x
Subject(s) - medicine , neovascular glaucoma , ophthalmology , iris (biosensor) , glaucoma , diabetic retinopathy , computer security , computer science , biometrics , diabetes mellitus , endocrinology
Purpose To present the anti‐VEGF treatment in neovascular glaucoma following proton beam irradiation in uveal melanomas. Methods Prospective evaluation on 69 cases of iris neovascularisation and neovascular glaucoma treated with anti‐VEGF intraocular injections. Results Iris neovascularisation was classified as pupillary 26%, sectorial 16%, tuffts 15% and diffused 43%. A sectorial iris ischemia related to proton beam irradiation was present in 64% of the cases. Following an observation period of 6 months to 3 years a normalisation of the intraocular pressure (less than 20 mm Hg) was obtained in 84% of the cases. Regression of iris tortuosity was observed in 77% of the cases. Regression of the iris neovascularisation in 68 % of the cases and reduction of diffusion of the dye in 67% of the cases. A remodelling of the iris ischemia was observed in 32% of the cases. Conclusion The intraocular injections of anti‐VEGF drugs in selected cases is a promising therapeutic approach for the treatment of iris neovascularisation and neovascular glaucoma related to proton beam irradiation of uveal melanomas.